SUNPHARMA Q1 FY27 Guidance vs Delivery (SUNPHARMA Management Mirror)

Q1 FY27 Consolidated Revenue Growth Reported at 10.5% YoY; FY27 Guidance Reaffirmed at High Single-Digit Contingent on FX Impacts

In the Mar'26 Qtr concall, management initiated guidance for high single-digit consolidated top-line growth for FY27 based on current regulatory and macro assumptions. In the Jun'26 Qtr concall, management reaffirmed this high single-digit consolidated revenue growth guidance for the full year FY27, advising caution regarding potential exchange-rate translation impacts. For the Jun'26 Qtr, the reported actual Quarterly Financial Results showed revenue of INR 1,52,999 million, up 10.5% YoY, while the Jun'26 Qtr concall noted sales of INR 1,51,836 million (10.1% YoY growth).